These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8673530)

  • 1. No evidence of a higher risk of progression to AIDS in patients with HIV-1-related severe thrombocytopenia.
    Galli M; Musicco M; Gervasoni C; Ridolfo AL; Niero F; Rusconi S; Riva A; Voltolin L; Lupo A; Lovicu GF; Radice D; Moroni M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):268-75. PubMed ID: 8673530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful zidovudine therapy for HIV-related severe thrombocytopenia. Report of a sustained remission.
    Peña JM; Arnalich F; Barbado FJ; Dominguez A; Mostaza J; Valencia ME; Vazquez JJ
    Acta Haematol; 1990; 83(2):86-8. PubMed ID: 2106201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial.
    Marroni M; Gresele P; Landonio G; Lazzarin A; Coen M; Vezza R; Sinnone MS; Boschetti E; Nosari AM; Stagni G; Nenci GG; Pauluzzi S
    Ann Intern Med; 1994 Sep; 121(6):423-9. PubMed ID: 8053616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
    Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
    AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy.
    Franzetti M; Adorni F; Oreni L; Van Den Bogaart L; Resnati C; Milazzo L; Antinori S; Galli M; Ridolfo AL
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):493-8. PubMed ID: 25230291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
    Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2018 May; 33(5):1108-1114. PubMed ID: 29023927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.
    Aledort LM; Hilgartner MW; Pike MC; Gjerset GF; Koerper MA; Lian EY; Lusher JM; Mosley JW
    BMJ; 1992 Jan; 304(6821):212-6. PubMed ID: 1346752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: modes of response and correlation with markers of HIV replication.
    Cinque P; Landonio G; Lazzarin A; Nosari AM; Ruggieri A; Coen M; Meraviglia P; Gringeri A; Gallo L; Quirino T
    Eur J Haematol; 1993 Jan; 50(1):17-21. PubMed ID: 8094675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.